Aim-Orbital granulocytic sarcoma is a localised tumour composed of cells of myeloid origin. Histological diagnosis can be diYcult in patients with poorly diVerentiated orbital tumours and no evidence of systemic leukaemia. The naphthol AS-D chloracetate esterase (Leder stain) and immunohistochemical stains for lysozyme and MAC387 were used to determine the staining characteristics of these tumours. A case series of seven patients with orbital granulocytic sarcoma is presented. Methods-Seven patients with orbital granulocytic sarcoma were studied. Haematoxylin and eosin, Leder, and lysozyme stained sections were available in seven cases. Unstained formalin fixed paraYn embedded sections of seven cases were available for immunohistochemical evaluation using the avidin-biotin-complex technique for MAC387. Results-The mean age of presentation of the orbital tumour was 8.8 years. Four patients presented with an orbital tumour before any systemic manifestations of leukaemia. In two cases the diagnosis of the orbital tumour and systemic leukaemia was made simultaneously. There was one case of established systemic myeloid leukaemia in remission with the subsequent development of orbital granulocytic sarcoma. Six of seven cases (86%) were positive for the Leder stain. Five of seven cases (71%) showed positive immunoreactivity with lysozyme. The immunohistochemical stain for MAC387 was positive in all seven cases (100%) including one case that was negative for both lysozyme and Leder stains. Conclusions-Orbital granulocytic sarcoma is a tumour that aVects children and can present with rapidly progressive proptosis. This tumour may develop before, during, or after the occurrence of systemic leukaemia. The combination of Leder and lysozyme stains is useful in the diagnosis of orbital granulocytic sarcoma. MAC387 may be a more reliable marker for orbital granulocytic sarcoma. (Br J Ophthalmol
Granulocytic sarcoma is a localised tumour comprised of malignant cells of myeloid origin. The first published report of granulocytic sarcoma was in 1811 by Allen Burns who described a green tumour involving the orbit. 1 Because these tumours can exhibit a characteristic green colour they were named chloroma. The green colour is caused by exposure of the enzyme myeloperoxidase to ultraviolet light. However, the gross appearance of these tumours is variable and up to 30% of granulocytic sarcomas do not display a green colour. This led Rappaport to rename these tumours granulocytic sarcoma in 1966. 2 Granulocytic sarcoma has been known by a variety of names including myeloblastoma, myelocytoma, chloroleukaemia and the World Health Organisation currently favours the name myeloid sarcoma. 3 Granulocytic sarcoma may occur as a manifestation of a well established systemic myelogenic leukaemia or it may precede systemic manifestations of peripheral blood and bone marrow. This tumour may present in association with diVerent types of myeloid leukaemia including acute myelogenous leukaemia, chronic myelogenous leukaemia with or without blast crisis, and other myeloproliferative disorders. 4 When granulocytic sarcoma precedes the development of leukaemia it usually heralds the development of peripheral blood and bone marrow involvement within 1 year. 4 5 Granulocytic sarcoma may be found in a variety of locations throughout the body including the orbit. 4 6 7 Orbital granulocytic sarcoma typically aVects children and young adults and must be diVerentiated from other orbital tumours that typically aVect this age group. 6 When a patient has a history of leukaemia and then develops orbital granulocytic sarcoma the diagnosis is usually not diYcult. However, when the orbital tumour precedes the development of systemic leukaemia the diagnosis can be diYcult for both clinician and pathologist. In addition, these tumours are often poorly diVerentiated making diagnosis more diYcult. 8 The diVerential diagnosis includes malignant lymphoma, rhabdomyosarcoma, and neuroblastoma.
Histological features of myeloid diVerentiation such as eosinophilic granules within the cytoplasm may be helpful in establishing a diagnosis. However, these findings are often absent and not specific to granulocytic sarcoma. 9 The naphthol-AS-D chloracetate esterase stain (Leder stain) greatly improved the ability of the pathologist to identify cells that contain myeloperoxidase. Similarly, immunohistochemical staining using antilysozyme antibodies for detection of lysozyme has proved useful in the identification of myeloid cells. Each of these stains in combination or alone is helpful when positive; however, a negative stain does not rule out granulocytic sarcoma. 9 We present seven well documented cases of orbital granulocytic sarcoma. We studied the clinical features and compared the use of the Leder stain and two immunohistochemical markers for myeloid cells-lysozyme and MAC387. 
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Materials and methods
Results
Clinical data are summarised in Table 1 . The age of presentation ranged from 5 months to 14 years with a mean age of 8.8 years. The orbital tumour preceded the development of systemic leukaemia in four cases. The mean time to development of systemic leukaemia was 5 months in these patients. In two cases the diagnosis of the orbital tumour and systemic leukaemia was made simultaneously. There was one case of established leukaemia in remission with development of orbital granulocytic sarcoma 8 months later.
Selected case reports
ORBITAL TUMOUR PRECEDES THE DEVELOPMENT OF LEUKAEMIA
Patient 1
A nine year old Latin-American boy was admitted to the hospital for rapidly progressive proptosis of the right globe. Two weeks before admission his right eye became painful. The patient had no previous illnesses.
Ophthalmic examination revealed right upper and lower lid oedema with proptosis and chemosis of the right eye ( Fig 1A) .
Computed tomography (CT) revealed a large irregular mass in the right superior orbit approximately 2 cm in diameter. Systemic examination, including a complete blood count and chest x ray, was negative.
An excisional biopsy revealed a greenish tumour, 20 mm in diameter. Histopathological examination revealed an infiltrating neoplasm composed of poorly diVerentiated cells with round or reniform nuclei, prominent nucleoli, and many mitotic figures. The scant to moderate cytoplasm contained eosinophilic granules. The Leder, lysozyme, and MAC387 stains were positive (Fig 1B, C, D) . A diagnosis of orbital granulocytic sarcoma was made.
Eleven months after the onset of the orbital tumour, the patient developed acute myelogenous leukaemia with blast cells in the peripheral blood. The patient underwent polychemotherapy.
ORBITAL TUMOUR AND LEUKAEMIA DISCOVERED SIMULTANEOUSLY
Patient 5
A 5 month old Spanish boy was admitted to the paediatric unit for evaluation of rapidly progressive proptosis of the left globe. Five days before admission his left eye became proptotic with left upper lid fullness and epiphora.
The initial ocular examination revealed unilateral left globe proptosis with downward and outward displacement of the eye without any signs of inflammation. A firm mass measuring approximately 5 × 5 mm could be palpated in the superior nasal quadrant of the left orbit.
A complete physical examination was unremarkable. CT revealed a homogeneous mass with uniform contrast enhancement located in the left superior orbit, involving the lacrimal gland.
The Leder stain was positive. Immunohistochemistry was negative for actin-desmin and L26 (CD 20) , and positive for LCA (CD 45), lysozyme, and MAC387.
A bone marrow biopsy demonstrated a monomorphic hypercellular proliferation of Male  R  OGS  11 months  2  9 years  Female  L  OGS  25 days  3  11 years  Female  R  OGS  3 months  4  10 years  Male  L  OGS  3 months  5  5 months  Male  L  OGS and leukaemia  Simultaneous  6  8 years  Male  R  OGS and leukaemia  Simultaneous  7 14 years Male R Leukaemia 8 months' remission *All seven patients presented with rapidly progressive proptosis. †OGS denotes patients who presented with orbital granulocytic sarcoma before any evidence of systemic leukaemia. OGS and leukaemia denotes patients who developed orbital granulocytic sarcoma and leukaemia simultaneously. Leukaemia denotes patients who had leukaemia before developing orbital granulocytic sarcoma.
‡Time interval between orbital granulocytic sarcoma and systemic leukaemia.
blastic cells. Some of the cells revealed small eosinophilic granules. The Leder and lysozyme stains were both positive. A subsequent complete blood cell count 10 days after admission revealed leukaemic cells. A diagnosis of acute myeloid leukaemia with orbital granulocytic sarcoma was made.
The patient underwent polychemotherapy. The patient currently is in remission 3 months after the initial admission awaiting autologous bone marrow transplant. CT demonstrated a large homogeneous mass in the left orbit. A biopsy was performed. Histological examination revealed a monotonous proliferation of poorly diVerentiated cells. The nuclei were round to oval with nuclei indented. There were prominent nucleoli and moderate mitotic activity. There is scant cytoplasm with no eosinophilic granules. The Leder stain was positive. A diagnosis of orbital granulocytic sarcoma was made. The patient was again treated with chemotherapy and has since been in remission.
PATHOLOGY
The seven tumours were classified as diVerentiated or poorly diVerentiated based on the presence or absence of granulocytic diVerentiation such as cytoplasmic eosinophilic granules and nuclear changes. Two of the cases were classified as diVerentiated and five cases were poorly diVerentiated. The Leder stain was positive in six of seven cases (86%). Five of seven cases were positive for lysozyme (71%), while all seven cases were positive for MAC387 (100%) ( Table 2 ). All seven cases were negative for CD 20, CD 43, desmin, and cytokeratin stains while only one cases was weakly positive for LCA. All five cases of orbital lymphoma demonstrated negative immunoreactivity with lysozyme and MAC387 ( Table 2) .
Discussion
Granulocytic sarcoma of the orbit can present in infancy to 61 years of age. 6 Despite this broad age range of presentation, these tumours
Figure 1 (A) Nine year old boy with proptotic right globe. (B) Histopathological section of orbital tumour showing malignant proliferation invading fat (haematoxylin and eosin, ×26). (C) High magnification showing immunoreactive cells (arrow) using lysozyme antibody (anti-lysozyme, ×128). (D) Positive immunohistochemical stain (arrow) of the orbital tumour using MAC387 (MAC387 stain, ×104).
typically present in children with a mean age of approximately 7 years. 6 12 This is consistent with the mean age of 8.8 years in this study.
Granulocytic sarcoma can occur in a variety of locations throughout the body including the orbit. 4 6 7 12 The most common sites of involvement are bone, soft tissues, lymph nodes, skin, and kidney. 4 7 Bone involvement is usually subperiosteal and most frequently located in the vertebrae, sternum, orbit, and cranium. 7 In Liu et al's study of 23 necropsy cases of granulocytic sarcoma, exophthalmos was present in seven cases and was the most common observable sign of tumour nodule. 7 Certain paediatric populations are known have a higher incidence of orbital granulocytic sarcoma. Reports in the literature indicate that African, Middle Eastern, East Asian, and Latin American children have a disproportionately higher incidence. 6 7 12-14 This series also supports geographic variation of this condition as all of the cases were of Spanish descent. This study also revealed a slight male predominance which is in accordance with previously published literature. 4 6 7 The clinical features of orbital granulocytic sarcoma can vary considerably. Proptosis is the most common presenting clinical sign. 6 7 12 In fact, Zimmerman and Font found 29 of 33 patients with orbital granulocytic sarcoma presented with signs of proptosis. 6 Grossniklaus and Wojno described a case presenting as periorbital cellulitis which represented myeloblastic invasion of eyelid dermis. 15 Various other presentations have been described including lacrimal gland involvement, eyelid tumour, post-traumatic, iris tumour, uveitis, conjunctival mass, and scleral mass. 6 15-19 The most puzzling feature of orbital granulocytic sarcoma is its variable temporal onset relative to the development of systemic leukaemia. The occurrence of the orbital granulocytic sarcoma before the development of systemic leukaemia is not uncommon and was demonstrated in 29 of 33 cases (88%) in the largest study of orbital granulocytic sarcoma by Zimmerman and Font. 6 Numerous other instances of this phenomenon can be found in the literature. 18 20 The subsequent development of leukaemia usually occurs within 1 year. [4] [5] [6] [7] The AFIP series by Zimmerman and Font showed that the vast majority of cases had haematological evidence within 2 months. 6 However, there are reports of prolonged intervals between the development of granulocytic sarcoma and systemic leukaemia varying from 2 to 16 years. 5 21 In our series, the development of orbital granulocytic sarcoma occurred before any evidence of systemic leukaemia in four of seven cases (57%) with a mean time to development of leukaemia in either the peripheral blood or bone marrow of 5 months.
The diVerential diagnosis of orbital granulocytic sarcoma can be challenging, particularly when there is no evidence of systemic leukaemia. It is most frequently confused with malignant lymphoma, but can also be confused with rhabdomyosarcoma, neuroblastoma, and other poorly diVerentiated tumours of childhood. 6 8 22 cannot be overemphasised that any tumour of the head and neck region, including the orbit, can potentially represent infiltration by malignant myeloid cells. 23 In patients with known systemic leukaemia CT may help to distinguish between granulocytic sarcomas from haematomas and abscesses, which are possible complications of leukaemia. 24 However, in patients who develop granulocytic sarcoma before leukaemia, CT or magnetic resonance imaging features are not specific enough to distinguish granulocytic neoplasms from other tumours. 24 25 To establish the diagnosis of orbital granulocytic sarcoma a biopsy is often required. There is a correlation between the degree of diVerentiation of these tumours and the accuracy of the initial diagnosis. Blastic tumours are correctly diagnosed 38% of the time, poorly diVerentiated tumours 47% of the time, and well diVerentiated tumours 54% of the time. 4 Typically, these tumours are composed of a monotonous invasive proliferation of malignant cells. The nuclei can vary from round in undiVerentiated cells, to indented in more differentiated cells. Nucleoli are frequently prominent and the number of mitotic figures is variable. Histological diVerentiation between granulocytic sarcoma and lymphoma may be facilitated if the tumour reveals cells with large nuclei with blastic chromatin and prominent nucleoli as this finding is rare in lymphomas. 9 The amount of cytoplasm and the presence of eosinophilic granules varies depending on the degree of diVerentiation of the cells. The cytoplasm is scant with no granules in undiVerentiated cells whereas in more diVerentiated cells the cytoplasm may be more abundant and exhibit cytoplasmic granules. Granulocytic differentiation when present is clearly helpful in establishing the diagnosis. However, Niemen et al found in their series that only 20% of theses tumours have a significant degree of diVerentiation. 4 Electron microscopy has been shown to be useful in establishing the diagnosis of granulocytic sarcoma. 9 However, it is rarely used and since the development of the Leder stain and immunohistochemistry, electron microscopy is not required to establish the diagnosis. 4 The development of the Leder and immunohistochemical stains have enhanced the ability of the pathologist to establish the diagnosis of granulocytic sarcoma. The Leder stain identifies cells with esterase activity. This stain can be used on formalin fixed paraYn embedded sections. 9 The Leder stain has been shown to be positive in approximately 75% of cases in two retrospective series on granulocytic sarcoma. 4 26 The results using the Leder stain in our study are similar to those previously published. A positive Leder stain is supportive of the diagnosis of granulocytic sarcoma but a negative stain does not rule out the diagnosis.
The immunohistochemical stain using antilysozyme antibody identifies cells that contain the enzyme lysozyme. The use of this marker in identifying tumours of myeloid origin has been established. 4 26 The lysozyme stain has been shown to be positive in 60% to 89% of cases in previous studies of granulocytic sarcoma. 4 26 More importantly, Neimen et al have shown that 98% of cases were identified positive for either Leder or lysozyme stains. 4 Because one of the cases in our series gave negative results with both the Leder and lysozyme stains, we examined the use of monoclonal antibody MAC387. All seven cases stained with MAC387 demonstrated immunoreactivity. For the vast majority of cases, the combination of Leder and lysozyme stains will establish the diagnosis of granulocytic sarcoma. 4 However, in cases of extremely poorly diVerentiated tumour in which the Leder and lysozyme stains give negative results, but clinical suspicion is high, MAC387 may prove useful in establishing the diagnosis.
Conclusions
Orbital granulocytic sarcoma may develop before, during, or after the occurrence of leukaemia in the peripheral blood and bone marrow. Histological diagnosis of granulocytic sarcoma can be diYcult in children with no evidence of leukaemia, so a high index of suspicion by both the clinician and the pathologist is important in order to make the diagnosis. Special stains and immunohistochemistry play an important role in the diagnosis. The use of lysozyme and Leder stains in combination is useful in establishing the diagnosis of granulocytic sarcoma. MAC387 stain may provide additional information in cases in which the Leder and lysozyme stains give negative results and clinical suspicion is high.
